Comparison · NCT00955487-sae
Inhaled Nitric Oxide (iNO) vs Placebo (Nitrogen): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Inhaled Nitric Oxide (iNO) vs Placebo (Nitrogen): serious adverse events. Trial comparisons, record NCT00955487-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00955487-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.458 | 0.337 | 0.583 | wilson | |
| Risk in group 2 | 0.646 | 0.525 | 0.751 | wilson | |
| Risk difference, group 1 minus group 2 | -0.189 | -0.349 | -0.0137 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.708 | 0.509 | 0.986 | log | |
| Odds ratio, group 1 over group 2 | 0.462 | 0.225 | 0.951 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Inhaled Nitric Oxide (iNO) than on Placebo (Nitrogen) | 5.3 | 2.87 | 73 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Inhaled Nitric Oxide (iNO) | Participants will receive a low concentration of iNO until they are 30 weeks corrected gestational age or for 14 days if they were born at 29 weeks or more.~Inhaled Nitric Oxide (iNO) will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx). | 27 | 59 | EG000 |
| Group 2 | Placebo (Nitrogen) | Participants will receive Placebo until they are 30 weeks corrected gestational age or for 14 days if they were born at 29 weeks or more.~Placebo will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx). | 42 | 65 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns
- NCT number
- NCT00955487
- Phases
- PHASE2
- Conditions
- Bronchopulmonary Dysplasia
- Interventions
- Inhaled Nitric Oxide (iNO), Nitrogen (placebo)
- Lead sponsor
- University of Colorado, Denver
- Results first posted
- 2017-05-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00955487?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00955487-sae